SCHEMBL6097335

SCHEMBL6097335

Cc1ccccc1C(=O)c1ccc(Nc2ccccc2CCNCCCN2CCOCC2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 10/20 0.54
MAPK12 P53778 10/20 0.54
MAPK11 Q15759 10/20 0.54
MAPK14 Q16539 10/20 0.54
SMN1; SMN2 Q16637 2/20 0.43
AVPR2 P30518 1/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK10 P53779 1/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096501 0.91 MAPK14 (0.61) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL6094744 0.85 MAPK13 (0.53) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL6098502 0.82 MAPK13 (0.57) MAPK13MAPK12MAPK11MAPK14
SCHEMBL6096703 0.82 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL6097278 0.80 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL6099284 0.80 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14MAPK8
SCHEMBL6096528 0.79 MAPK14 (0.59) MAPK13MAPK12MAPK11MAPK14
SCHEMBL6098537 0.78 MAPK13 (0.56) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL6096253 0.78 MAPK14 (0.60) MAPK13MAPK12MAPK11MAPK14AVPR2
SCHEMBL6097137 0.77 MAPK14 (0.71) MAPK13MAPK12MAPK11MAPK14AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF MAPK13 2918/4885MAPK12 2155/4885MAPK11 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.